Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €20.65 EUR
Change Today -0.104 / -0.50%
Volume 4.0K
EUZ On Other Exchanges
Symbol
Exchange
Xetra
OTC US
As of 4:35 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

eckert & ziegler strahlen un (EUZ) Snapshot

Open
€20.89
Previous Close
€20.75
Day High
€20.97
Day Low
€20.64
52 Week High
06/6/14 - €27.39
52 Week Low
01/6/15 - €16.70
Market Cap
109.3M
Average Volume 10 Days
5.8K
EPS TTM
€1.28
Shares Outstanding
5.3M
EX-Date
06/4/15
P/E TM
16.1x
Dividend
€0.60
Dividend Yield
2.91%
Current Stock Chart for ECKERT & ZIEGLER STRAHLEN UN (EUZ)

Related News

No related news articles were found.

eckert & ziegler strahlen un (EUZ) Related Businessweek News

No Related Businessweek News Found

eckert & ziegler strahlen un (EUZ) Details

Eckert & Ziegler Strahlen & Medizintechnik AG and its subsidiaries provide isotope technology for medical, scientific, and industrial use primarily in Europe. The company’s Radiation Therapy segment produces and distributes medical devices for brachytherapy, a form of radiotherapy that treats cancer by irradiation from a short distance. This segment offers seeds for the treatment of localised prostate cancer; high dose rate (HDR) afterloaders to treat gynaecological cancers and other tumour sites; applicators for intraluminal, interstitial, intracavitary, and intraoperative treatments, as well as surface mould treatments; and support software of HDR planning. The Radiation Therapy segment also provides products for temporary brachytherapy of eye cancers and radiotherapy accessories. This segment’s products and equipment are intended for use by oncologists, radio-therapists, urologists, ophthalmologists, and medical physicists. Its Isotope Products segment provides sealed and unsealed radiation sources for medical imaging, industrial gauging, measurement and analysis, reference, calibration, and environmental monitoring sources and solutions; and bulk radioisotopes for pharmaceutical, therapeutic, and industrial product manufacturers. This segment offers custom and one-off design and manufacturing services. The company’s Radiopharma segment operates in the field of molecular imaging and nuclear medicine supplying various radiopharmaceuticals, radiochemicals, and related equipment for the synthesis and radiochromatography of PET/SPECT tracers and other radioisotopes. This segment offers products in the categories of radiosynthesis technology, radiochromatography, and radionuclides. Its Environmental Services segment collects, measures, sorts, treats, and packs low level radioactive waste from hospitals, research institutes, and industry for its final disposal. Eckert & Ziegler Strahlen & Medizintechnik AG was founded in 1992 and is headquartered in Berlin, Germany.

Founded in 1992

eckert & ziegler strahlen un (EUZ) Top Compensated Officers

Chairman of The Executive Board, Chief Execut...
Total Annual Compensation: €512.0K
Head of Radiopharma Segment, Member of The Ex...
Total Annual Compensation: €292.0K
Head of Radiation Therapy Segment, Member of ...
Total Annual Compensation: €282.0K
Compensation as of Fiscal Year 2013.

eckert & ziegler strahlen un (EUZ) Key Developments

Eckert & Ziegler Strahlen & Medizintechnik AG Reports Consolidated Earnings Results for the Year 2014; Provides Earnings Guidance for the Year 2015

Eckert & Ziegler Strahlen & Medizintechnik AG reported consolidated earnings results for the year 2014. For the year, the company generated earnings of EUR 2.3 million in the 2014 fiscal year, which is 25 % less than in the prior year. The decline in consolidated profit after taxes and minority interests to EUR 6.8 million, or EUR 1.28 per share, was mainly attributable to reduced sales in markets affected by the crises in the Middle East and Ukraine, among others. In addition, the Radiation Therapy segment was negatively impacted by restructuring expenses, tax adjustments and the absence of extraordinary income that had contributed to the prior year's positive result. The Group increased overall sales in 2014 by 9 % to EUR 127.3 million. This development was mainly attributable to organic growth in the Isotope Products segment as well as in the Radiopharma segment. Acquisition-related growth in the Radiation Therapy segment was weaker than expected and sales of existing products also declined in this segment. Due to lower profits, cash flow from operating activities of EUR 10.7 million is down EUR 4.0 million year on year. Cash outflows from investment activities, which declined by EUR 6.6 million to EUR 10.8 million as a result of fewer acquisitions, provided support in this context. Accordingly, there was less need for financing, so that the Group reduced loans in 2014 by net EUR 4.1 million. In the 2015 fiscal year, sales of more than EUR 133 million are expected and net profit will likely exceed the amount generated in 2013 of EUR 1.71 per share.

Eckert & Ziegler Strahlen & Medizintechnik AG Announces Earnings Results for the Full Year of 2014; Proposes Dividend for the Year 2014

Eckert & Ziegler Strahlen & Medizintechnik AG announced earnings results for the full year of 2014. For the year, the company increased its sales by 9% to EUR 127 million. Net profit was EUR 6.8 million of EUR 1.28 per share against EUR 9.0 million or EUR 1.71 per share a year ago. The decline in earnings was mainly due to the Radiation Therapy segment, which earned EUR 0.91 per share less than in the prior year. The company announced that at the annual general meeting on June 3, 2015, the executive board and the supervisory board will propose a dividend of EUR 0.60 per share entitled to a dividend compared to EUR 0.60 per share paid in prior year.

Eckert & Ziegler Strahlen & Medizintechnik AG, Annual General Meeting, Mar 06, 2015

Eckert & Ziegler Strahlen & Medizintechnik AG, Annual General Meeting, Mar 06, 2015.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EUZ:GR €20.65 EUR -0.104

EUZ Competitors

Market data is delayed at least 15 minutes.

Company Last Change
General Electric Co $24.86 USD +0.06
View Industry Companies
 

Industry Analysis

EUZ

Industry Average

Valuation EUZ Industry Range
Price/Earnings 15.2x
Price/Sales 0.8x
Price/Book 1.1x
Price/Cash Flow 15.2x
TEV/Sales 0.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ECKERT & ZIEGLER STRAHLEN UN, please visit www.ezag.de. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.